

Equatorial Guinea

Population 2016

1.2 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.19 (0.13–0.26)	16 (11–21)
Mortality (HIV+TB only)	0.37 (0.28–0.46)	30 (23–38)
Incidence (includes HIV+TB)	2.2 (1.9–2.5)	181 (159–205)
Incidence (HIV+TB only)	1.1 (0.93–1.3)	91 (76–107)
Incidence (MDR/RR-TB)**	0.11 (0.055–0.17)	9.2 (4.5–14)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.12 (0.1–0.13)	0.81 (0.7–0.91)	0.93 (0.81–1)
Males	0.14 (0.12–0.15)	1.1 (1–1.3)	1.3 (1.1–1.4)
Total	0.25 (0.22–0.29)	2 (1.7–2.2)	2.2 (1.9–2.5)

TB case notifications, 2016	
Total cases notified	1 487
Total new and relapse	1 428
- % tested with rapid diagnostics at time of diagnosis	7%
- % with known HIV status	6%
- % pulmonary	90%
- % bacteriologically confirmed among pulmonary	66%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	65% (57–74)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.25 (0.2–0.31)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	45	56%
- on antiretroviral therapy	45	100%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			78 (45–110)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	29% (21–39)	
% notified tested for rifampicin resistance	<1%	64%	105
MDR/RR-TB cases tested for resistance to second-line drugs			32
Laboratory-confirmed cases		MDR/RR-TB: 32, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 32, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	43%	1 191
Previously treated cases, excluding relapse, registered in 2015	20%	51
HIV-positive TB cases registered in 2015	45%	293
MDR/RR-TB cases started on second-line treatment in 2014	33%	3
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically